Carrolee Barlow
Directeur/Bestuurslid bij SUPERNUS PHARMACEUTICALS, INC.
Vermogen: 504 161 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Carrolee Barlow
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 17 | |
Public Company | Pharmaceuticals: Major | 11 | |
Fascinate Therapeutics , Inc.
Fascinate Therapeutics , Inc. Miscellaneous Commercial ServicesCommercial Services Fascinate Therapeutics, Inc. is a clinical neurological diseases company. The company is based in San Diego, CA. The CEO of the company is Kisub Lee.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Carrolee Barlow via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | General Counsel General Counsel Sales & Marketing | |
New Rhein Healthcare Investors
New Rhein Healthcare Investors Investment ManagersFinance New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania. | Investment Managers | Chief Operating Officer Consultant / Advisor | |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Chairman Director/Board Member | |
University of Maryland | College/University | Undergraduate Degree Doctorate Degree | |
CIMA Labs, Inc.
CIMA Labs, Inc. Pharmaceuticals: OtherHealth Technology CIMA Labs, Inc. develops and manufactures prescription and over-the-counter pharmaceutical products using fast-dissolve drug delivery technologies. It develops orally disintegrating technology based OraSolv and DuraSolv tablets. It also develops tranmucosal tablets that can be administered sublingually. The company is headquartered in Brooklyn Park, MN. | Pharmaceuticals: Other | Chief Executive Officer Chairman | |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Chairman Chief Executive Officer | |
Yale University | College/University | Graduate Degree Undergraduate Degree | |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
ADAMAS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | President Director/Board Member | |
SCPHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
VANDA PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director of Finance/CFO Sales & Marketing | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Technical University of Denmark | College/University | Graduate Degree Doctorate Degree | |
ABLYNX | Biotechnology | Director/Board Member | |
MORGAN STANLEY | Investment Managers | Corporate Officer/Principal | |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer | |
STJ Advisors LLP
STJ Advisors LLP Investment ManagersFinance STJ Advisors LLP provides capital markets advisory services. The private company is based in London, UK and has subsidiaries in Hong Kong. The British company was founded in 2008 by John James Moore St. John. | Investment Managers | Corporate Officer/Principal | |
ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member | |
GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member | |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
CMR Surgical Ltd.
CMR Surgical Ltd. Medical SpecialtiesHealth Technology CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
BIOTALYS NV | Chemicals: Agricultural | Director/Board Member | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
OXFORD BIOMEDICA PLC | Biotechnology | Director/Board Member | |
MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Public Communications Contact | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Creabilis SA | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 17 |
Zwitserland | 8 |
Verenigd Koninkrijk | 8 |
Frankrijk | 6 |
Nederland | 5 |
Sectoraal
Health Technology | 38 |
Finance | 5 |
Consumer Services | 4 |
Commercial Services | 3 |
Health Services | 2 |
Operationeel
Director/Board Member | 164 |
Corporate Officer/Principal | 62 |
Independent Dir/Board Member | 46 |
Chairman | 41 |
Chief Executive Officer | 32 |
Sterkste connecties
Insiders | |
---|---|
Georges Gemayel | 33 |
Martijn Kleijwegt | 33 |
Anders Hedegaard | 30 |
Charles Newhall | 29 |
Rémi Droller | 29 |
Catherine Moukheibir | 29 |
Martin N. Bonde | 22 |
John Siebert | 16 |
Jack Khattar | 16 |
Frederick Hudson | 14 |
Kim Stratton | 14 |
Kevin T. Anderson | 10 |
Stephanie Okey | 9 |
Stefan Schwabe | 9 |
Timothy Dec | 9 |
- Beurs
- Insiders
- Carrolee Barlow
- Bedrijfsconnecties